Analysts have been eager to weigh in on the Healthcare sector with new ratings on MoonLake Immunotherapeutics (MLTX – Research Report), Structure Therapeutics, Inc. Sponsored ADR (GPCR – Research Report) and Aligos Therapeutics (ALGS – Research Report).
MoonLake Immunotherapeutics (MLTX)
In a report issued on March 11, Thomas Smith from Leerink Partners maintained a Buy rating on MoonLake Immunotherapeutics, with a price target of $73.00. The company’s shares closed last Tuesday at $46.04.
According to TipRanks.com, Smith is a top 100 analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for MoonLake Immunotherapeutics with a $75.30 average price target, which is a 59.5% upside from current levels. In a report issued on February 26, LifeSci Capital also maintained a Buy rating on the stock with a $75.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Structure Therapeutics, Inc. Sponsored ADR (GPCR)
Leerink Partners analyst David Risinger reiterated a Buy rating on Structure Therapeutics, Inc. Sponsored ADR on March 8. The company’s shares closed last Tuesday at $35.29.
According to TipRanks.com, Risinger is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Structure Therapeutics, Inc. Sponsored ADR with a $85.80 average price target, which is a 141.7% upside from current levels. In a report issued on March 8, BMO Capital also initiated coverage with a Buy rating on the stock with a $83.00 price target.
Aligos Therapeutics (ALGS)
Leerink Partners analyst Roanna Ruiz maintained a Hold rating on Aligos Therapeutics on March 8. The company’s shares closed last Tuesday at $0.87.
According to TipRanks.com, Ruiz has 0 stars on 0-5 stars ranking scale with an average return of
Currently, the analyst consensus on Aligos Therapeutics is a Moderate Buy with an average price target of $7.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on MLTX:
- MoonLake Immunotherapeutics Unveils Psoriatic Arthritis Breakthroughs
- MoonLake price target raised to $100 from $75 at H.C. Wainwright
- MoonLake announces improvements with Nanobody sonelokimab over 24 weeks in PsA
- MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day
- 3 Best Stocks to Buy Now, 3/5/2024, According to Top Analysts
